| Ytd | -79.45% | |
| 1y | -82.85% |
| Open | 1.55 | Prev Close | 1.57 | Low | 1.55 | High | 1.73 | Mkt Cap | 11.40M |
| Vol | 108.68K | Avg Vol | 258.79K | EPS | -2.45 | P/E | N/A | Forward P/E | N/A |
| Beta | -0.28 | Short Ratio | 0.65 | Inst. Own | 12.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.60 | 200-d Avg | 2.77 | 1yr Est | 17.33 |
MTVA News
Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consisten
All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing P
All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 m
CAMBRIDGE, Mass., June 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotec
POMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a lead
GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT
DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evide
Solidion Technology, Inc. (NASDAQ: STI) rose 50.55% in pre-market trading on Friday after announcing
CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotech
48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Ex
Discover why MetaVia Inc. (NASDAQ: MTVA) stock is surging on Friday following new peer-reviewed data
MetaVia Inc. (NASDAQ: MTVA) shares drop over 10% on Thursday due to profit-taking despite announcing
CAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotech
Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial
Three Late-Breaking Posters Highlight DA-1726, a GLP-1/Glucagon Dual Agonist, and Vanoglipel, a GPR1
48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, I
CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotech
16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obe
48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Im
16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in O
MetaVia Inc. (NASDAQ: MTVA - Get Free Report) saw a significant growth in short interest in February
Patent Portfolio Includes 48 Granted and Pending Patents in the U.S., Europe, Japan, China and other
CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotec
